On the contrary to what has been initially anticipated, several independent studies came to the conclusion that FasL/Fas axis neutralization would extend the benefits of cancer immunotherapy: (i) one major role of FasL/Fas in the immune cells is to promote the RICD of activated T lymphocyte at the end of the immune response. This evidence concerns the gene FAS and cancer.